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  23 
Abstract 24 
Leu341 has been predicted from crystal structure as an important residue for thyroid hormone 25 
receptor (TR) β function, but this has never been confirmed in functional studies. Here, we 26 
describe a novel p.L341V mutation as a cause of resistance to thyroid hormone β, suggesting an 27 
important role for Leu341 in TRβ function. In silico and in vitro studies confirmed that 28 
substituting Leu341 with Val and other non-polar amino acids impairs sensitivity of TRβ for T3 29 
with various degrees, depending on their side-chain size and orientation.  30 
  31 
Introduction 32 
Mutations in the THRB gene that affect the function of the thyroid hormone receptor (TR) 33 
β cause resistance to thyroid hormone (RTH) β. The biochemical characteristics are elevated T4 34 
and T3 with non-suppressed TSH concentrations. Based on the TRβ1 crystal structure, Leu341 35 
has been predicted as an important residue for the binding to T3 (1, 2). We here verify the crucial 36 
role of Leu341 in T3 binding and TRβ1 functions, driven by the identification of a novel 37 
p.L341V mutation in an RTHβ patient. 38 
Patient 39 
 A 12-year-old Thai girl (II.3) presented with short stature (height 134 cm [-3.17 SDS], 40 
weight 27.2 kg, BMI 15.1 kg/m2 [-1.83 SDS]), diffused goiter and palpitations (heart rate 41 
144/min). She had been misdiagnosed with Graves’ disease and treated with methimazole for 3 42 
years. During treatment, she had fluctuating thyroid hormone and increased TSH concentrations. 43 
Her older sister (II.2) and mother (I.2) also suffered from presumed Graves’ disease, for which 44 
the mother had undergone a subtotal thyroidectomy and subsequently developed post-operative 45 
hypothyroidism which required high dose of L-thyroxine (300 µg/day) treatment. Their thyroid 46 
function tests showed high T4 and T3 with non-suppressed TSH concentrations, suggesting 47 
RTHβ (Fig.1A and Supplementary Fig.S1).  48 
Results 49 
After obtaining informed consent, sequencing of exons 7-10 of the THRB gene identified 50 
a novel heterozygous p.L341V (c.1021C>G) mutation in all affected members. This mutation is 51 
not present in public databases (dbSNP, 1000 Genomes, and Exome Aggregation Consortium 52 
[ExAC]). 53 
Based on the crystal structure (PDB-ID: 3GWS (3)), Leu341 is located in the T3-binding 54 
pocket of wild-type (WT) TRβ1, and its aliphatic side-chain forms hydrophobic interactions with 55 
the outer ring of the T3 molecule and surrounding residues to maintain the shape and integrity of 56 
the T3-binding pocket (Fig.1B and Supplementary Fig.S2). TRβ1-L341V and three artificial 57 
mutants (L341I, L341A, and L341F) with hydrophobic side-chains of different sizes and 58 
structural properties were subsequently modeled (Fig.1B). Because the side-chain of Val is 59 
shorter than that of Leu and has a different orientation, the interaction with T3 and surrounding 60 
residues of TRβ1-L341V was predicted to be disturbed. Given its very small side-chain, these 61 
alterations were even more pronounced in the Ala substituent. Even though the size and 62 
branched-chain character of Ile is similar to Leu, the altered side-chain orientation affects direct 63 
contacts with T3 and interactions with the surrounding residues in TRβ1-L341I. Although TRβ1-64 
L341F was predicted to slightly alter the architecture of the T3-binding pocket, the direct 65 
interactions with T3 and most of the surrounding residues were preserved.  66 
  In vitro studies confirmed the functional impairment of these mutants. In [125I]T3 67 
competitive binding assays, the dissociation constant (Kd) of all mutants was higher than WT, 68 
indicating a reduced T3 affinity. Interestingly, the shift in Kd was related to the size of the 69 
introduced side-chain and the distance to T3 and surrounding residues (Fig.1D). Substitution by 70 
Ala and Val, which have a smaller side-chain size than Leu, Ile and Phe, produced larger shifts in 71 
Kd. The shift of T3-induced transcriptional activity of the mutant receptors on the DR4-TRE 72 
luciferase reporter showed a similar trend. The half maximal effective T3 concentration (EC50) of 73 
all mutants was higher than that of WT, indicating their impaired transcriptional activity 74 
(Fig.1E). In addition, the degree of the shift in EC50 also depended on the size and orientation of 75 
the side-chain. The EC50 of co-expressed WT and TRβ1-L341V was also significantly higher (3-76 
fold) than that of WT only, suggesting a dominant-negative effect of the TRβ1-L341V (Fig.1C). 77 
Together, these in vitro studies support an important role for Leu341 in T3 binding and receptor 78 
function.  79 
Discussion 80 
 Here, we demonstrate that Leu341 of TRβ is crucial for T3 binding, prompted by the 81 
identification of a novel L341V THRB mutation in an RTHβ family. Our in-depth functional 82 
studies confirm the crucial role of this residue for TRβ function which had been predicted by  83 
crystallographic studies and the identification of a previously reported L341P mutation in a 84 
patient with RTHβ (4).  85 
The in silico models used in this study correctly predict the degree of receptor 86 
impairment as found in our in vitro studies. In addition, the creation of artificial mutations based 87 
on the in silico modeling gains more detailed insight about the T3-TRβ interaction. It suggests 88 
that the exact side-chain size and orientation at residue 341 are of vital importance for T3 89 
binding and hence receptor activity. These findings also indicate that the in silico prediction is a 90 
good approach to further explore the role of certain residues in TRβ function and may enhance 91 
our understanding of the pathogenic effects of mutations therein. 92 
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  123 
Figure 1. (A) The pedigree demonstrates three RTHβ patients in the family and their TFTs 124 
(TSH, thyroid-stimulating hormone; TT4, total thyroxine; FT4, free thyroxine; TT3, total 125 
triiodothyronine; FT3, free triiodothyronine; Anti-TPO, anti-thyroid peroxidase; Anti-TG, anti-126 
thyroglobulin; TRAb, thyrotropin receptor autoantibody). (B) Crystal structure of T3-bound WT 127 
TRβ1 (PDB-ID: 3GWS) in which the side chain of the affected Leu341 is depicted in red. 128 
Arg282 and His435 form hydrogen bonds with the carboxyl group of the alanine side-chain and 129 
phenolhydroxyl group of T3, respectively (purple dashed lines). Together with Leu330, Phe272, 130 
and Leu346, Leu341 forms a hydrophobic pocket accommodating the two phenolic rings of the 131 
T3 molecule through hydrophobic interactions (green lines) which it stabilizes the hydrophobic 132 
pocket. Structural models of the L341V and three artificial mutants (L341A, L341I, and L341F) 133 
showing the side-chain size and orientation toward the T3 molecule and surrounding residues of 134 
the different residue side-chains. All mutants were predicted to disturb these interactions to 135 
various degrees, with the L341F having the smallest impact. (C) Co-transfection of WT with 136 
TRβ1-L341V alters transcriptional activity of WT in a dominant-negative manner (mean ± SEM 137 
of four independent experiments performed in triplicate). (D) The [125I]T3 dissociation curves 138 
show the diverse severity of T3 binding impairment of the mutants (mean ± SEM of three 139 
independent experiments performed in duplicate). (E) Transcriptional activity of the mutant 140 
receptors is impaired, as indicated by the right-shifted of T3-induced dose-response curves tested 141 
on DR4-TRE (mean ± SEM of three independent experiments performed in triplicate). (Insert) 142 
Immunoblotting confirms the expression of all receptor constructs in Jeg3 cells.  143 
 144 
 145 
Supplementary Materials  146 
Assessment of thyroid function 147 
 Thyroid function tests (TSH, FT4, and FT3) of the index patient were evaluated using 148 
electro-chemiluminescence immunoassay kit (Roche Diagnostic, Mannheim, Germany).  149 
DNA extraction and mutation analysis 150 
 Genomic DNA was extracted from peripheral blood leukocytes by QIAamp® DNA Mini 151 
Kit (Qiagen, Hilden, Germany). Exons 7-10 of the THRB gene [GeneBank: NM_000461.4], 152 
including exon-intron boundaries, were amplified (see Supplementary Table S1 for primers). 153 
Sequencing was performed as described previously (1). The exon carrying the mutation was re-154 
amplified and sequenced to exclude a PCR error. The study was approved by the Medical Ethics 155 
Committee of the Faculty of Medicine, Chiang Mai University, Thailand. 156 
In silico prediction of mutant TRβ1 function 157 
YASARA Structure Software (YASARA Bioscience GmbH, Vienna, Austria) (2) was 158 
used to model the TRβ1-L341V patient’s mutation and three artificial mutants (L341A, L341I 159 
and L341F) into a T3-bound WT TRβ1 crystal structure (PDB-ID: 3GWS) (3) using the side-160 
chain substitution tool. Side-chain orientations were optimized using SCWALL (Side-Chain 161 
conformations With ALL available methods) (4, 5) after which the final models were minimized 162 
without further constraints. All images were created using YASARA Structure and Pov-Ray v3.6 163 
software (www.povray.org). 164 
DNA constructs and mutagenesis 165 
The human TRβ1 cDNA was amplified and subcloned into the EcoRI and XbaI sites of 166 
the pcDNA3 expression vector fused at the 5’-end to the sequence encoding the FLAG-epitope 167 
tag and downstream of an optimized Kozak sequence (see Supplementary Table S1 for primers). 168 
The TRβ1-L341V patient’s mutation (c.1021C>G) and three artificial mutants, including L341A, 169 
L341I and L341F, were introduced using the QuickChange II Mutagenesis kit (Agilent 170 
Technologies, Amstelveen, The Netherlands) according to manufacturers’ protocol (see 171 
Supplementary Table S1 for primers). Sequences of mutant constructs were confirmed by Sanger 172 
sequencing. 173 
[125I]T3 competitive binding assay 174 
Human FLAG-tagged TRβ1 WT and mutant (L341V, L341A, L341I and L341F) 175 
receptor proteins were synthesized in reticulocyte lysate using the TnT® T7 Quick Coupled 176 
Transcription/Translation System (Promega, Leiden, The Netherlands). The protein lysate was 177 
incubated with 0.02 nM of [125I]T3 in 0.5 mL binding buffer (20 mM Tris, pH 8.0, 50 mM KCl, 178 
1 mM MgCl2, 10% glycerol, 5 mM DTT) and 0-10,000 nM unlabeled T3 for 2 hours at 30°C. 179 
Protein-bound [125I]T3 was captured by filtering through a nitrocellulose filter membrane 180 
(Millipore HA filters, 0.45 µm) under vacuum. The data was corrected for non-specific binding 181 
(counts bound at 10,000 nM unlabeled T3) and expressed as percentage maximal [125I]T3 182 
binding (counts bound at 0 nM unlabeled T3). The [125I]T3 displacement curve and the 183 
dissociation constant (Kd) were computed by GraphPad Prism program version 5.0 (GraphPad, 184 
La Jolla, CA) and shown as mean ± standard error of the mean (SEM) of three independent 185 
experiments performed in duplicate. 186 
Cell culture and transfection 187 
JEG3 cells were cultured and transfected as previously described (6). In brief, 20 ng of 188 
FLAG-tagged WT or mutant TRβ1 expression vectors and 120 ng of luciferase reporter 189 
constructs containing direct repeat (DR4) thyroid hormone response element (TRE) (7), as well 190 
as 60 ng pMaxGFP transfection control, were transiently transfected into cells in thyroid 191 
hormone-depleted medium using Xtreme Gene 9 transfection reagent (Roche Diagnostics, 192 
Almere, NL). To determine the effect of TRβ1-L341V on WT function (dominant-negative 193 
effect), we co-expressed WT and TRβ1-L341V receptors (1:1 equimolar ratio), or either WT or 194 
TRβ1-L341V with empty vector (EV) (as gene dose control). After 24 hours, cells used for 195 
luciferase assays were incubated in DMEM/F12 medium supplemented with 0.1% bovine serum 196 
albumin and containing 0-10,000 nM T3 for 24 hours.  197 
Immunoblotting 198 
To determine the expression of FLAG-tagged TRβ1 WT and mutants in JEG3 cells, 199 
nuclear proteins were extracted as described previously with slight modifications (8). Briefly, 200 
cells were swollen on ice for 15 min in buffer A (10 mM Hepes, 10 mM KCl, 0.1 mM EDTA, 1 201 
mM DTT, pH 7.9) supplemented with the Complete Protease Inhibitor cocktail (Roche 202 
Diagnostics) and were lysed by addition of 0.6% NP40. The nuclei were pelleted by 203 
centrifugation for 10 min at 2500 g and extracted for 45 min in buffer C (20 mM HEPES, 0.4 M 204 
NaCl, 1 mM EDTA, 1 mM DTT, Complete Protease Inhibitors, pH 7.9) at 4˚C. After 205 
centrifugation for 15 min at 20000 g, the supernatants containing nuclear proteins were collected 206 
and diluted in buffer D (20 mM HEPES, 1 mM EDTA, Complete Protease Inhibitors, pH 7.9). 207 
Immunoblotting was performed as previously described (6). The FLAG-tagged TRβ1 and 208 
Histone 3 (as loading control) were detected by FLAG-M2 antibody (#F1804 Sigma-Aldrich) 209 
and Histone 3 (H3; 1B1B2) antibody (#14269 Cell Signaling Technology), respectively, at a 210 
1:1000 dilution and visualized by Enhanced Chemiluminescence (Thermofisher Scientific) on 211 
the Alliance 4.0 Uvitec platform (Uvitec Ltd). 212 
Luciferase assay 213 
 Luciferase activity of WT and mutant receptors was measured using the Dual Glo 214 
Luciferase kit (Promega, Leiden, The Netherlands) as previously described (1). The ratio 215 
between luciferase and GFP was calculated to adjust for transfection efficiency. Data were 216 
expressed as percentage maximal response of WT and half maximal effective T3 concentration 217 
(EC50) and maximal response calculated using GraphPad Prism program version 5.0 (GraphPad, 218 
La Jolla, CA). The results are shown as mean ± SEM of at least three independent experiments 219 
performed in triplicate. 220 
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